Pfizer suspends worldwide studies for tanezumab in osteoarthritis

Pfizer has suspended worldwide clinical trials of its investigational pain drug, tanezumab, for osteoarthritis at the request of the US FDA after some patients receiving the drug experienced a worsening of their osteoarthritis that led to joint replacement. Trials for this population had reached the Phase III stage.

Pfizer has suspended worldwide clinical trials of its investigational pain drug, tanezumab, for osteoarthritis at the request of the US FDA after some patients receiving the drug experienced a worsening of their osteoarthritis that led to joint replacement. Trials for this population had reached the Phase III stage.

The drug is also in Phase II/III development for chronic low back pain and Phase II for cancer pain, interstitial...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Dermatological

Galderma Gets First Biologic To Market With Nemluvio Approval

 

Nemluvio is a first-in-class IL-31 inhibitor that the US FDA approved for prurigo nodularis. 

Dupixent Data Could Scratch A Regulatory Itch

 

New pivotal data on Regeneron and Sanofi’s antibody in chronic urticaria are underwhelming, though probably sufficient for approval. A green light may beckon in bullous pemphigoid, too.

Leo Shrugs Off Timber Drug Failure As Revenues Roar

 
• By 

The Danish firm’s dermatology products have made significant strides in the past six months, leading to an upwards revision of its sales forecast for full-year 2024.

Leo’s Congenital Ichthyosis Candidate Fails Phase III Study

 
• By 

TMB-001, a topical formulation of isotretinoin, missed its primary endpoint in the ASCEND study and will not be filed for approval. Leo is turning its attention to hand eczema and dealmaking.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.